Company’s portable, non-invasive brain sensing system Nautilus NeuroWave™ is designed to rapidly and reliably detect abnormal neurological conditions, including ischemic stroke, vasospasm, and concussion

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jan Medical and Brainlab today announced a collaboration and Series B funding efforts to complete two clinical trials and the subsequent filing of two product 510(k)s with the FDA. Brainlab will also add a member representative to the Jan Medical Board of Directors.

“Partnering with and investing in an innovative company, with goals aligned with Brainlab’s vision, is an exciting opportunity for us. Jan Medical’s specialization in adjacent markets to our own provides us a vehicle to expand our footprint in the neuro-tech space”

Jan Medical has successfully completed a vasospasm study at UCSF Hospital led by Principal Investigator (PI) Professor Wade Smith M.D. Patients recovering from subarachnoid hemorrhagic (SAH) can suffer symptomatic spasm within the cerebral vasculature leading to cerebral infarction. Current monitoring technologies in the neurocritical care units are not universally applicable, are highly operator dependent and are not always available when needed. The Nautilus NeuroWave™ is designed to provide simple, reliable monitoring to all patients recovering from SAH and to provide timely information for those managing these critically ill patients.

In other developments, an investigator-led clinical trial by PI Prof. Paul Auerbach M.D., Stanford University, is investigating the possible utility of the Nautilus NeuroWave™ to detect and track recovery from sports-related concussion.

“Partnering with and investing in an innovative company, with goals aligned with Brainlab’s vision, is an exciting opportunity for us. Jan Medical’s specialization in adjacent markets to our own provides us a vehicle to expand our footprint in the neuro-tech space,” said Stefan Vilsmeier, President and CEO of Brainlab.

“This Series B funding further validates the potential of our brain-sensing platform, Nautilus NeuroWave^TM, especially in the current challenging economic environment that continues to keep most investors on the sidelines,” added Paul Lovoi, Ph.D., President and CEO of Jan Medical.

“Our Nautilus NeuroWave™ system is designed to give healthcare providers a reliable non-invasive device designed to detect cerebral abnormalities in clinical settings where conventional imaging technologies are not effective or in the case of concussion, non-existent. As a result, patient outcomes will be enhanced, as healthcare providers will have clinically relevant and timely information to treat their patients faster, at lower cost, and with less risk.”

Brainlab develops, manufactures and markets software-driven medical technology, enabling access to improved, more efficient, less-invasive patient treatments. Core products revolve around less-invasive image guided surgery technology, more accurate and effective radiation therapy, and integration through planning and collaboration systems that bring patient data and physicians together. Brainlab technology currently powers treatments in the fields of neurosurgery, radiation oncology, orthopedics, ENT, CMF, spine, and trauma. Privately held since its formation in Munich, Germany, in 1989, Brainlab has more than 5,000 systems installed in about 80 countries. Brainlab employs 1,120 people in 17 offices worldwide, including 290 Research & Development engineers, who form a crucial part of the product development team. To learn more, visit www.brainlab.com.

Jan Medical is a privately held, emerging medical technology company that has developed the world’s first and only portable brain sensing system designed as a rapid aid to diagnosis of abnormal neurological conditions such as concussion and stroke. www.janmedical.com

CAUTION: THE JAN MEDICAL SYSTEM IS AN INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.